Supporting long-term HIV treatment success: Real-world durability of B/F/TAF
18 Sep 2026
byMIMS Editorial Team
Advances in antiretroviral therapy (ART) have transformed HIV management, with life expectancy among people living with HIV (PLHIV) now comparable to that of the general population. This makes choosing a durable regimen that can sustain treatment success over the long term increasingly important. Recent real-world evidence highlights the durability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), an integrase strand transfer inhibitor (INSTI)–based three-drug regimen, in both treatment-naïve and treatment-experienced settings.